Amref Health Africa Statement on Mosquirix™ (RTS,S) (malaria vaccine candidate)

"The announcement that GSK’s malaria vaccine candidate has passed a major step by receiving a positive opinion from the European Medicines Agency is indeed worthy of celebration, especially so for the thousands of children who are living with the risk of malaria across sub-Saharan Africa and the world.

In Africa, a child dies every minute from malaria. As an organization that works with Africa’s most vulnerable communities, Amref Health Africa is optimistic that this vaccine - when finally availed and coupled with key malaria prevention tools - will help to create an end-game in the long-standing fight against malaria.
Amref Health Africa, who has been in partnership with GSK for more than 27 years, congratulates the GSK and PATH scientists who have worked tirelessly for many years, supported by the Bill & Melinda Gates Foundation, to reach this milestone. Our first initiatives with GSK were on malaria prevention. We understand that more needs to be done and that this is not a silver bullet, but the world is watching this scientific milestone."

Dr. Githinji Gitahi, Amref Health Africa global CEODr Githinji Gitahi, CEO, Amref Health Africa.